Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we talk about how moves by the Trump administration are impacting investment in mRNA, see the law firm DLA Piper create a coalition to lobby on Medicare price negotiations, and more.
Under Trump, is investment in mRNA cooling?
The Trump administration’s decision to cut nearly $500 million in federal support for the development of mRNA vaccines is being felt across the biotech industry — but not always in the same way.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
